A new report reveals that the U.S. adult obesity rate has declined to 37% in 2025, down from a record 39.9% in 2022, as more Americans turn to weight loss drugs like GLP-1 injectables. With 7.6 million fewer obese adults, is this the start of a healthier trend?
A recent Gallup survey reveals a rapid increase in the use of injectable obesity treatments, correlating with a drop in obesity rates among U.S. adults. Discover the implications and future of these groundbreaking medications!
Eli Lilly's new obesity pill, orforglipron, faces tough competition but could disrupt the weight loss market. Despite underwhelming trial results, analysts see potential for success due to manufacturing advantages and pricing strategies.
Discover the crucial role of diet and exercise alongside GLP-1 medications for effective weight loss. Experts reveal tips to maximize benefits and minimize side effects.
A groundbreaking study shows that bariatric surgery leads to five times more weight loss than GLP-1 drugs like semaglutide. Discover why surgery remains the gold standard in obesity treatment.
A new regulator confirmation links Ozempic to a rare eye condition, NAION, affecting diabetes patients. This revelation raises concerns about potential blindness risks associated with semaglutide. Discover the implications for users.
Recent clinical trials show that GLP-1 weight loss medications like Zepbound are more effective for women than men, prompting researchers to explore the biological and societal reasons behind this phenomenon.
In a groundbreaking clinical trial, Mounjaro proves to be nearly 50% more effective than Ozempic. This article explores the implications of this major breakthrough in weight loss treatments.
A groundbreaking trial reveals that Mounjaro is more effective than Wegovy for weight loss, achieving a 20% reduction over 72 weeks compared to Wegovy's 14%. Discover the implications for obesity treatment!
A groundbreaking study reveals semaglutide, already known for weight loss and diabetes treatment, is effective for fatty liver disease, benefiting two-thirds of participants in a recent trial. This could revolutionize treatment options!
